Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) has announced its intention to complete a non-brokered private placement of 750,000 units priced at $0.20 each, targeting gross proceeds of up to $150,000 from a strategic investor. The medical device company, which is commercialising IzoView™, a dedicated breast CT imaging system, says the funds will support general working capital. The offering includes warrant coverage at a $0.30 exercise price, adding a potential additional capital layer for the company.

Key Points

  • Izotropic Corporation (CSE: IZO) is a Vancouver and Casablanca-based medical device company focused on breast CT imaging
  • The company intends to issue 750,000 units at $0.20 per unit to a single strategic investor for gross proceeds of up to $150,000
  • Each unit includes one common share and one warrant exercisable at $0.30 per share for three years from closing; all securities carry a four-month-and-one-day statutory hold period
  • Investors may be watching for regulatory approval of the offering and any update on IzoView™ commercialisation progress

Unit Structure and Warrant Terms of the IZO Private Placement

Each unit issued under the offering consists of one common share and one transferable warrant. The warrants entitle the holder to acquire one additional common share at an exercise price of $0.30 for a period of three years from the closing of the offering. The $0.20 unit price sits below the $0.30 warrant strike, providing a built-in premium structure. All securities issued will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities legislation, limiting near-term secondary market activity.

Proceeds Directed to General Working Capital for IzoView™ Commercialisation

Izotropic has stated that the gross proceeds of up to $150,000 will be used for general working capital purposes. The company is advancing IzoView™, described as a dedicated breast CT imaging system designed for more accurate screening and diagnosis of breast cancers. The release notes that IzoView™ has not yet been approved or cleared for sale, meaning the company remains in a pre-revenue commercialisation phase. Investors may be watching how this working capital injection supports the company's regulatory and operational activities across its Vancouver and Casablanca operations.

Regulatory Conditions and U.S. Securities Restrictions

Completion of the offering remains conditional on receiving all necessary regulatory approvals, among other conditions. The securities will not be registered under the United States Securities Act of 1933, and the announcement explicitly states that no offering or sale may occur in the United States absent applicable registration or exemption. The release clarifies that the news announcement does not constitute an offer to sell or solicitation of an offer to buy securities in any jurisdiction where such activity would be unlawful. The immediate share price impact was not clear from available public information.